However, those short-cuts are often dangerous as it is difficult to quantify the abundance and heterogeneity of ABC transporters in particular tumours and we have no definitive proof that inhibitors increase drug accumulation in cancer cells without unacceptable toxicity. The gene discussed is ABCG2; the disease is neoplasm.